It appears that Mesoblast has also completed the submission of its rolling BLA to the FDA for approval of its product candidate for acute gvhd.
From today's anouncement:
About MesoblastSee below for comparison:
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the- shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast completed submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates.
From previous announcement dated 27/11/2019 (Mesoblast Chairman Message to 2019 AGM)
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-theshelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast’s proprietary manufacturing process yields industrial-scale, frozen, off-the
You can verify the abvove info yourself by reading these two announcements.
- Forums
- ASX - By Stock
- Submission of rolling BLA to the FDA for acute GVHD completed
It appears that Mesoblast has also completed the submission of...
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
-0.038(3.52%) |
Mkt cap ! $1.187B |
Open | High | Low | Value | Volume |
$1.07 | $1.07 | $1.03 | $2.851M | 2.723M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 217625 | $1.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 115690 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 98017 | 1.035 |
30 | 280367 | 1.030 |
27 | 384842 | 1.025 |
25 | 957663 | 1.020 |
9 | 44945 | 1.015 |
Price($) | Vol. | No. |
---|---|---|
1.040 | 127194 | 32 |
1.045 | 118855 | 18 |
1.050 | 117538 | 15 |
1.055 | 141908 | 13 |
1.060 | 135661 | 11 |
Last trade - 12.02pm 21/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online